Figure 2
Effect of TP and/or EP3 antagonism in PE-precontracted, NOS-inhibited or endothelium-denuded rat mesenteric resistance arteries. (A) The control response evoked by PGI2 (1 μM; CTL) in L-NAME-treated WKY vessels precontracted with PE (3 μM) and that obtained with the EP3 antagonist L798106 (1 μM; +L; bottom) or the TP antagonist SQ29548 (+SQ; 10 μM). (B) Representative traces showing the response evoked by PGI2 (top) and that obtained with L798106 (1 μM; +L; bottom) in (A). (C) The control response evoked by PGI2 in PE-precontracted, L-NAME-treated SHR vessels and that obtained with SQ29548 (+SQ), with L798106 (+L), or with L798106 and SQ29548 (+L/SQ). In A and C, n = 5 for each; ** P < 0.01; + P < 0.05 and ++ P < 0.01 vs. the value in +L. (D) Representative traces with summarized values showing the control response evoked by PGI2 (top) in PE-precontracted, endothelium-denuded SHR vessels (top) and that obtained with L798106 (+L; bottom). FC (4 min): the value of force change relative to that of PE 4 min after the application of PGI2. ** P < 0.01.
